Company Statement
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Biocon Pharma Limited, a subsidiary of Biocon Limited, has received approval from Health Canada for micafungin for injection in 50 mg and 100 mg doses. The approved product is used to treat various Candida infections including candidemia, acute disseminated candidiasis, and Candida peritonitis in adults and children four months and older. It is also approved for esophageal candidiasis treatment and prophylaxis of Candida infections in stem cell transplant patients. This approval strengthens Biocon's integrated biosimilars and generics portfolio in the Canadian market.
The Health Canada approval expands Biocon's product portfolio internationally, potentially opening a new revenue stream from the Canadian pharmaceutical market. This regulatory milestone is positive for shareholders as it demonstrates the company's ability to secure approvals for its subsidiary's products.